Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carcinoma)
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 22 Oct 2018 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 20 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2019.